Program
solbinsiran
Also written as “LY3561774” and “Solbinsiran”.
Its studies are mostly in Hypertriglyceridemia · Hyperlipoproteinemias · Dyslipidemias, led by Eli Lilly.
Furthest: phase 2, since Feb 23, 20223 company-led studies, 1 open or runningNext primary completion: Mar 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 31 open or running | phase 2since Feb 23, 2022 | Nov 24, 2020 | Mar 2027phase 2 · NCT07269210 |
- Named in Eli Lilly’s own pipeline as
Solbinsiran
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 24, 2020First study: phase 1 study in DyslipidemiasFirst studyNCT04644809 · 74 enrolled · United States
- Feb 23, 2022Phase 2 study in DyslipidemiasNCT05256654 · 205 enrolled · United States, Argentina, Canada and more
- Nov 26, 2025Phase 2 study in HypertriglyceridemiaNCT07269210 · 60 planned · United States, Canada, China and more
Ahead
- Mar 2027Primary completion: phase 2 study in HypertriglyceridemiaNCT07269210
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07269210Hypertriglyceridemia · United States, Canada, China and more | 2 | Recruiting | Mar 2027 | 60 |
| NCT05256654Dyslipidemias · United States, Argentina, Canada and more | 2 | Completed | Mar 4, 2024 | 205 |
| NCT04644809Dyslipidemias · United States | 1 | Completed | May 17, 2022 | 74 |
How it is read
Names in the registry
- “LY3561774”, 2 entries
- “Solbinsiran”, 1 entry
Conditions, from the studies’ own filings
- Hypertriglyceridemia, 1 study
- Hyperlipoproteinemias, 1 study
- Dyslipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.